Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Top Links You Must Click On


Genoa Pharmaceuticals and McMaster University to collaborate on Idiopathic Pulmonary Fibrosis Research

SAN DIEGO, Jan. 16, 2013 /PRNewswire/ -- Genoa Pharmaceuticals, a leader in the field of pulmonary fibrosis, today announced it is collaborating with Dr. Martin Kolb and researchers at McMaster University to characterize the in vivo advantages and potential clinical impact of Genoa's lead program, inhaled GP-101 (aerosol pirfenidone) for the treatment of IPF.  The research will combine Genoa's expertise in aerosol drug delivery with McMaster's expertise in exploring mechanisms of pulmonary fibrosis and managing patients with IPF.

"Genoa is very excited about the opportunity to collaborate with Dr. Kolb and McMaster University to better understand how inhaled GP-101 may benefit IPF patients," said Mark Surber, Ph.D., Genoa's Founder, President and Chief Scientific Officer. "Genoa is committed to establishing academic relationships with leading institutions to further advance its efforts to develop novel treatments for IPF."

"We are very interested to evaluate novel therapies such as GP-101 to better understand the molecular effects and in vivo relationship to the human disease," said Dr. Martin Kolb, M.D., Ph.D. & Associate Professor in the Division of Respirology, within the Department of Medicine Pathology & Molecular Medicine at McMaster University.  "We are pleased to collaborate with Genoa as we believe GP-101 has the potential to be a key treatment for IPF."

About Genoa Pharmaceuticals

Genoa Pharmaceuticals, Inc. is committed to developing improved therapies for the treatment of IPF. Based in San Diego, Genoa's lead program, GP-101 (aerosol pirfenidone) is advancing towards the clinic for the treatment of IPF. Learn more at www.genoapharma.com

About Dr. Martin Kolb and McMaster University

Dr. Kolb is Associate Professor of Medicine at McMaster University and Research Director of the Firestone Institute for Respiratory Health. Dr. Kolb is a recognized expert in the field of lung fibrosis whose research activities focus on the biology of lung injury, repair and fibrosis, particularly in Idiopathic Pulmonary Fibrosis (IPF). He has a strong interest in growth factor biology (e.g. TGFβ and IL-1), extracellular matrix, and mesenchymal cell progenitors (mesenchymal stem cells and fibrocytes). In his lab he uses a variety of disease models to study biological mechanisms and also the efficacy of novel drugs in the preclinical setting. Small animal imaging with CT and PET is one of the exciting new research areas that Dr. Kolb pursues at McMaster in collaboration with other faculty members (Dr. Renee Labiris). Further, Dr. Kolb leads activities in biomarker development for lung fibrosis and he participates as Principal Investigator and Steering Committee members in numerous clinical trials on interstitial lung disease. He is elected Chair of the 18th International Colloquium on Lung Fibrosis in September 2014 (Tremblant, Quebec).

SOURCE Genoa Pharmaceuticals, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .
We often get asked “Should I use GridFS for file storage with MongoDB”. As with most things, the answer is a staunch “it depends”. GridFS looks like a great idea on paper - a virtual filesystem held within MongoDB which allows for larger than 16MB files to be held, synced and replicat...
The supply chain is evolving, and buyers need to analyze and predict, but also to manage risk. When Capgemini's business information management (BIM) practices unit needed to provide big data capabilities to its insurance company customers, it needed to deliver the right information t...
Some people believe good or bad things always happen in threes. I believe you will always be able to find three (and probably more) things that are good or bad and somewhat related, but sometimes I get surprised by the apparent coincidental appearance of several closely related “things...
This article defines long polling and presents a few techniques on how long polling could be used in Spring MVC web applications. Discussion covers both the AJAX and the server part of the solution as well as outlines a few possible options for implementation. The article compares perf...
Red Hat, Inc., on Wednesday announced that it has signed a definitive agreement to acquire eNovance, a provider of open source cloud computing services. Combined with Red Hat’s existing leadership in OpenStack, the addition of eNovance’s systems integration capabilities and engineering...
Hear from Red Hat leaders and industry experts on Tuesday, June 10, 2014, at 11am and see how Red Hat Enterprise Linux continues to deliver unmatched customer value, increased efficiency, and true strategic advantage for global customers across every industry. Attendees will learn mor...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE